Ponatinib and palbociclib combination in TKI-resistant CML —A case report
ConclusionThis combination treatment showed high clinical activity. However, biological activity needs to be further characterized in prospective clinical trials.
Source: Memo - Magazine of European Medical Oncology - Category: Cancer & Oncology Source Type: research
More News: Cancer & Oncology | Clinical Trials | Hematology | Leukemia | Stem Cell Therapy | Stem Cells | Study | Toxicology | Transplants